Nathalie Ibrahim

Nathalie Ibrahim

Auto-generated profile, based on publicly available information

Nathalie Ibrahim

Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DFDavid Fandrei
David Fandrei
JPJean Pegliasco
Jean Pegliasco
FPFlorence Pasquier
Florence Pasquier
NINathalie Ibrahim
Nathalie Ibrahim
MKMaria Kfoury
Maria Kfoury
JMJean Baptiste MICOL
Jean Baptiste MICOL
Purpose: PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D-mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D-mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D-mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53-mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.


3 June 2025
Verified
Other
Open access
DFDavid Fandrei
David Fandrei
JPJean Pegliasco
Jean Pegliasco
FPFlorence Pasquier
Florence Pasquier
NINathalie Ibrahim
Nathalie Ibrahim
MKMaria Kfoury
Maria Kfoury
JMJean Baptiste MICOL
Jean Baptiste MICOL
Supplementary Data 1 from Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders